中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
10期
22-24
,共3页
阿司匹林%替普瑞酮%胃黏膜损伤
阿司匹林%替普瑞酮%胃黏膜損傷
아사필림%체보서동%위점막손상
Aspirin%Teprenone%Gastric mucosa injury
目的 观察替普瑞酮对阿司匹林导致的胃黏膜损伤的保护作用,为阿司匹林等非甾体类抗炎药所致胃黏膜损伤的防治提供理论依据.方法 收集需要长期服用阿司匹林的患者84例,根据治疗方法不同分成阿司匹林组(A组)和替普瑞酮+阿司匹林组(B组),每组42例.记录用药3、6个月及1年时消化道症状、不良反应以及粪隐血试验和胃镜检查评分情况.结果 随着治疗时间的延长,A组和B组用药3、6个月及1年时消化道症状发生率[4.76％ (2/42)、9.52％(4/42)、21.43％(9/42),0、2.38％(1/42)、11.90％(5/42)]、粪隐血试验评分[(0.052±0.006)、(0.183±0.014)、(0.315±0.028)分,(0.006±0.001)、(0.037±0.008)、(0.206±0.013)分]和胃镜检查评分[(0.072±0.011)、(0.283±0.018)、(0.453±0.034)分,(0.008±0.003)、(0.046±0.010)、(0.243±0.016)分]均相应增加,差异有统计学意义(P＜ 0.05或＜0.01).B组用药3、6个月及1年时消化道症状发生率、粪隐血试验评分和胃镜检查评分均显著低于A组,差异有统计学意义(P＜ 0.05或＜0.01).两组患者在用药3、6个月及1年时的消化道不良反应发生率比较差异无统计学意义(P＞0.05).结论 替普瑞酮可以有效防治阿司匹林导致的胃黏膜损伤,且不良反应发生率低,值得临床推广应用.
目的 觀察替普瑞酮對阿司匹林導緻的胃黏膜損傷的保護作用,為阿司匹林等非甾體類抗炎藥所緻胃黏膜損傷的防治提供理論依據.方法 收集需要長期服用阿司匹林的患者84例,根據治療方法不同分成阿司匹林組(A組)和替普瑞酮+阿司匹林組(B組),每組42例.記錄用藥3、6箇月及1年時消化道癥狀、不良反應以及糞隱血試驗和胃鏡檢查評分情況.結果 隨著治療時間的延長,A組和B組用藥3、6箇月及1年時消化道癥狀髮生率[4.76％ (2/42)、9.52％(4/42)、21.43％(9/42),0、2.38％(1/42)、11.90％(5/42)]、糞隱血試驗評分[(0.052±0.006)、(0.183±0.014)、(0.315±0.028)分,(0.006±0.001)、(0.037±0.008)、(0.206±0.013)分]和胃鏡檢查評分[(0.072±0.011)、(0.283±0.018)、(0.453±0.034)分,(0.008±0.003)、(0.046±0.010)、(0.243±0.016)分]均相應增加,差異有統計學意義(P＜ 0.05或＜0.01).B組用藥3、6箇月及1年時消化道癥狀髮生率、糞隱血試驗評分和胃鏡檢查評分均顯著低于A組,差異有統計學意義(P＜ 0.05或＜0.01).兩組患者在用藥3、6箇月及1年時的消化道不良反應髮生率比較差異無統計學意義(P＞0.05).結論 替普瑞酮可以有效防治阿司匹林導緻的胃黏膜損傷,且不良反應髮生率低,值得臨床推廣應用.
목적 관찰체보서동대아사필림도치적위점막손상적보호작용,위아사필림등비치체류항염약소치위점막손상적방치제공이론의거.방법 수집수요장기복용아사필림적환자84례,근거치료방법불동분성아사필림조(A조)화체보서동+아사필림조(B조),매조42례.기록용약3、6개월급1년시소화도증상、불량반응이급분은혈시험화위경검사평분정황.결과 수착치료시간적연장,A조화B조용약3、6개월급1년시소화도증상발생솔[4.76％ (2/42)、9.52％(4/42)、21.43％(9/42),0、2.38％(1/42)、11.90％(5/42)]、분은혈시험평분[(0.052±0.006)、(0.183±0.014)、(0.315±0.028)분,(0.006±0.001)、(0.037±0.008)、(0.206±0.013)분]화위경검사평분[(0.072±0.011)、(0.283±0.018)、(0.453±0.034)분,(0.008±0.003)、(0.046±0.010)、(0.243±0.016)분]균상응증가,차이유통계학의의(P＜ 0.05혹＜0.01).B조용약3、6개월급1년시소화도증상발생솔、분은혈시험평분화위경검사평분균현저저우A조,차이유통계학의의(P＜ 0.05혹＜0.01).량조환자재용약3、6개월급1년시적소화도불량반응발생솔비교차이무통계학의의(P＞0.05).결론 체보서동가이유효방치아사필림도치적위점막손상,차불량반응발생솔저,치득림상추엄응용.
Objective To investigate the clinical efficacy of teprenone on aspirin-induced gastric mucosa injury and provide theoretical basis for protective mechanism.Methods A total of 84 patients who needed long time aspirin treatment were enrolled in this study.All the 84 cases were divided into two groups according to the treatment method:aspirin treatment group (group A,42 cases) and teprenone + aspirin treatment group (group B,42 cases).The gastrointestinal symptoms,adverse reactions,and fecal occult blood test and endoscopy score were recorded after treatment of 3 months,6 months and 1 year.Results The incidence of gastrointestinal symptoms [4.76％ (2/42),9.52％ (4/42),21.43％ (9/42),0,2.38％ (1/42),11.90％ (5/42)],fecal occult blood test score [(0.052 + 0.006),(0.183 + 0.014),(0.315 + 0.028) scores and (0.006 + 0.001),(0.037 + 0.008),(0.206 + 0.013) scores] and endoscopy score [(0.072 + 0.011),(0.283 + 0.018),(0.453 ± 0.034) scores and (0.008 + 0.003),(0.046 + 0.010),(0.243 ± 0.016)scores]was significantly increased in group A and group B along with the time of treatment (P ＜ 0.05 or ＜ 0.01).The incidence of gastrointestinal symptoms,fecal occult blood test score and endoscopy score was significantly lower in group B than that in group A after treatment of 3 months,6 months and 1 year (P ＜ 0.05 or ＜ 0.01).The incidence of gastrointestinal adverse reaction was no significant difference between two groups after treatment of 3 months,6 months and 1 year (P ＞ 0.05).Conclusion Teprenone shows effective activity against aspirin-induced gastric damage with a low incidence of adverse reactions,and it is worthy to spread in the clinical application.
